Latest in Inhalers Development
Over the period of time, the technology has advanced and improved MDI's or Metered Dose Inhalers. Right from formulations, canisters to mouthpieces, everything has radically changed for better. This has resulted into better delivery of drugs to the lungs.
The basic valve designs have also improved that leads to improved dosing consistency. Formerly, the dosage was dependent on valve orientation and it varied according to the quantity of formulation in the canister. The older CFC inhalers have registered inconsistent dosing within few hours of storage. However, the new and improved designs of valve show consistent dosage delivery with a storage period of nearly a week.
The dosage delivery also depends on temperature; CFC MDI's are very temperature sensitive. Any drop or increase in the same affects the dosing consistency. When MDI actuates, the formulation stored within gets atomized into minute drops (size usually varies from 10 to 40 microns) and as the evaporation starts, the size of droplets gradually decreases. For effective delivery of dosage, the droplets need to decrease speedily so that it percolates into the lungs. For better results, smaller the size of particles more effective is the formulation.
After checking the clinical data and related statistics, it has been observed that the CFC MDIs as well as DPIs have proved to be inefficient. However, the field of DPI is always innovating and research work is thoroughly conducted and results in effective and better updates Current products in market like approved DPI products deliver minute droplets into the lungs and the latest MDI's that are equipped with HFA propellants, can deliver better compared to the CFC MDIs or the DPIs available.
The surfactants are an important component and required to attain the requisite dosage reproducibility of HFA suspension MDIs, so that fast flocculation is achieved. The surfactants that are utilized in CFC suspension MDIs do not dissolve in HFA propellants and hence, additional co solvents are required to make the surfactant soluble. Different and advanced HFA-soluble excipients provide stable suspension formulations with a relatively good dosing reproducibility14-16.
Be it asthma or lung diseases, MDIs are widely used to treat variety of respiratory disorders. With each passing year, MDI's improve drastically, from CFC to HFA propellants, the development is noteworthy. As far as the drug delivery is concerned, HFA MDIs display more efficiency than DPIs or CFC MDIs. With deep research and studies, the efficacy can be further enhanced. The modern HFA MDIs can be used to treat variety of lung and systemic diseases owing to the effective delivery of large doses from the pharynx, right into the lungs.
The basic valve designs have also improved that leads to improved dosing consistency. Formerly, the dosage was dependent on valve orientation and it varied according to the quantity of formulation in the canister. The older CFC inhalers have registered inconsistent dosing within few hours of storage. However, the new and improved designs of valve show consistent dosage delivery with a storage period of nearly a week.
The dosage delivery also depends on temperature; CFC MDI's are very temperature sensitive. Any drop or increase in the same affects the dosing consistency. When MDI actuates, the formulation stored within gets atomized into minute drops (size usually varies from 10 to 40 microns) and as the evaporation starts, the size of droplets gradually decreases. For effective delivery of dosage, the droplets need to decrease speedily so that it percolates into the lungs. For better results, smaller the size of particles more effective is the formulation.
After checking the clinical data and related statistics, it has been observed that the CFC MDIs as well as DPIs have proved to be inefficient. However, the field of DPI is always innovating and research work is thoroughly conducted and results in effective and better updates Current products in market like approved DPI products deliver minute droplets into the lungs and the latest MDI's that are equipped with HFA propellants, can deliver better compared to the CFC MDIs or the DPIs available.
The surfactants are an important component and required to attain the requisite dosage reproducibility of HFA suspension MDIs, so that fast flocculation is achieved. The surfactants that are utilized in CFC suspension MDIs do not dissolve in HFA propellants and hence, additional co solvents are required to make the surfactant soluble. Different and advanced HFA-soluble excipients provide stable suspension formulations with a relatively good dosing reproducibility14-16.
Be it asthma or lung diseases, MDIs are widely used to treat variety of respiratory disorders. With each passing year, MDI's improve drastically, from CFC to HFA propellants, the development is noteworthy. As far as the drug delivery is concerned, HFA MDIs display more efficiency than DPIs or CFC MDIs. With deep research and studies, the efficacy can be further enhanced. The modern HFA MDIs can be used to treat variety of lung and systemic diseases owing to the effective delivery of large doses from the pharynx, right into the lungs.